Herzuma 420 mg powder for concentrate for solution for infusion, CYCLOPHOSPHAMIDE, Perjeta 420 mg concentrate for solution for infusion, CYCLOPHOSPHAMIDE, DS-8201a, PACLITAXEL, DOXORUBICIN, Herzuma 150 mg powder for concentrate for solution for infusion, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
D967RC00001
Phase 3 small_molecule active
Quick answer
Herzuma 420 mg powder for concentrate for solution for infusion, CYCLOPHOSPHAMIDE, Perjeta 420 mg concentrate for solution for infusion, CYCLOPHOSPHAMIDE, DS-8201a, PACLITAXEL, DOXORUBICIN, Herzuma 150 mg powder for concentrate for solution for infusion, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE for Early stage HER2-positive breast cancer (T stage >= T3, lymph node positive, or inflammatory) is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Early stage HER2-positive breast cancer (T stage >= T3, lymph node positive, or inflammatory)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active